Study summary · research use only
Cerebrolysin improves sciatic nerve dysfunction in a mouse model of diabetic peripheral neuropathy
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this mouse study, a type 2 diabetes model was established using a high-glucose, high-fat diet plus a single intraperitoneal injection of streptozotocin, and diabetic mice were then given intraperitoneal Cerebrolysin at 1.80, 5.39, or 8.98 mL/kg for 10 consecutive days. The number, diameter, and area of myelinated nerve fibers in the sciatic nerve were reported to increase after Cerebrolysin administration. Behavioral testing showed Cerebrolysin dose-dependently increased the slope angle in the inclined plane test, prolonged tail-flick latency and foot-licking time, and increased an index of sciatic nerve function compared with untreated diabetic mice. The authors state the anatomical and functional results suggest Cerebrolysin ameliorated peripheral neuropathy in this mouse model of type 2 diabetes.
Abstract
To examine the effects of Cerebrolysin on the treatment of diabetic peripheral neuropathy, we first established a mouse model of type 2 diabetes mellitus by administering a high-glucose, high-fat diet and a single intraperitoneal injection of streptozotocin. Mice defined as diabetic in this model were then treated with 1.80, 5.39 or 8.98 mL/kg of Cerebrolysin via intraperitoneal injections for 10 consecutive days. Our results demonstrated that the number, diameter and area of myelinated nerve fibers increased in the sciatic nerves of these mice after administration of Cerebrolysin. The results of several behavioral tests showed that Cerebrolysin dose-dependently increased the slope angle in the inclined plane test (indicating an improved ability to maintain body position), prolonged tail-flick latency and foot-licking time (indicating enhanced sensitivity to thermal and chemical pain, respectively, and reduced pain thresholds), and increased an index of sciatic nerve function in diabetic mice compared with those behavioral results in untreated diabetic mice. Taken together, the anatomical and functional results suggest that Cerebrolysin ameliorated peripheral neuropathy in a mouse model of type 2 diabetes mellitus.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.